ResearcherBeth Israel Deaconess Medical CenterActive in the last 2 years
Raghu Kalluri
Matched on ORCID iD 0000-0002-2190-547X; OpenAlex author ID A5004654560; NIH RePORTER profile ID 1858925. Sources: OpenAlex.
Their work
- Papers
- 31 (first author 0, last author 22)
- Trials
- 0
- Grants
- 7
- Labs led
- 2
- Collaborators
- 111
2014: 1 paper, 1 grant · 2015: 2 papers · 2016: 1 paper · 2017: 4 papers, 1 grant · 2018: 2 papers · 2019: 1 grant · 2020: 1 paper · 2021: 3 papers, 1 grant · 2022: 4 papers, 1 grant · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers, 1 grant · 2026: 4 papers, 1 grant
Papers 31
- Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
- Oncogenic KRAS Regulates Secretion of Extracellular Vesicles and Surface Membrane Charge via Regulation of Phosphatidylserine in Pancreatic Cancer. Last author DOI 10.1021/acsnano.6c08263↗
- Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer. Last author DOI 10.1038/s41467-026-75960-3↗
- CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. Last author DOI 10.1038/s44318-026-00854-5↗
- Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Last author DOI 10.1038/s41467-025-63718-2↗
- Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer. Co-author DOI 10.1038/s41556-025-01697-8↗
- Genetics and biology of pancreatic ductal adenocarcinoma. Co-author DOI 10.1101/gad.351863.124↗
- An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adt5511↗
- Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line … Co-author DOI 10.64898/2025.12.14.25342225↗
- Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/s41591-023-02694-w↗
- Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Last author DOI 10.1126/science.adh4567↗
- KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Last author DOI 10.1016/j.ccell.2023.07.002↗
- Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Last author DOI 10.1016/j.devcel.2023.07.025↗
- Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Last author DOI 10.1016/j.ccell.2022.06.011↗
- Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Last author DOI 10.1038/s41586-022-05062-9↗
- Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression. Co-author DOI 10.1136/gutjnl-2021-324994↗
- Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. Last author DOI 10.1158/2159-8290.cd-20-1484↗
- Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Last author DOI 10.1016/j.ccell.2021.02.007↗
- Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. Last author DOI 10.1016/j.celrep.2021.108990↗
- Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras G12D in pancreatic cancer. Last author DOI 10.26508/lsa.202000875↗
- Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-19-0597↗
- Generation and testing of clinical-grade exosomes for pancreatic cancer. Last author DOI 10.1172/jci.insight.99263↗
- Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent metastasis program. Last author DOI 10.15252/emmm.201809085↗
- Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Last author DOI 10.1038/nature22341↗
- Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Last author DOI 10.1038/ncomms15095↗
- Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Last author DOI 10.1080/15384047.2017.1281499↗
- Multiple antibodies identify glypican-1 associated with exosomes from pancreatic cancer cells and serum from patients with pancreatic cancer Last author DOI 10.1101/145706↗
- Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/nm.4082↗
- Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Last author DOI 10.1038/nature14581↗
- Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Last author DOI 10.1038/nature16064↗
- Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. Last author DOI 10.1074/jbc.c113.532267↗
Grants 7
- Biology and Function of Exosomes in Cancer R35CA263815↗
- Core C-Computational Core P01CA117969↗
- Mechanisms associated with organotropic metastasis R01CA252729↗
- Exosomes in Cancer Therapy R01CA213233↗
- Mechanisms of Alcohol Initiation of Chronic Pancreatic Diseases R21AA026462↗
- Employing mouse models to translate early detection of pancreas cancer R01CA195733↗
- Role of Fibroblasts, Myeloid Cells and Matrix in PDAC U01CA151925↗
Closest collaborators
The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kathleen M. McAndrews · 12 shared papers, 2018–2026 · strength 1.87
- Paper Oncogenic KRAS Regulates Secretion of Extracellular Vesicles and Surface Membrane Charge via Regulation of Phosphatidyl… DOI 10.1021/acsnano.6c08263↗
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. DOI 10.1126/science.adh4567↗
- Anirban Maitra · 8 shared papers, 1 shared grant, 2018–2026 · strength 1.82
- Krishnan K. Mahadevan · 7 shared papers, 2022–2026 · strength 1.15
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. DOI 10.1126/science.adh4567↗
- Paper Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. DOI 10.1038/s41467-025-63718-2↗
- Sujuan Yang · 9 shared papers, 2017–2025 · strength 1.05
- Paper Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. DOI 10.1038/s41467-025-63718-2↗
- Paper Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic … DOI 10.1016/j.ccell.2021.02.007↗
- Paper Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to pr… DOI 10.1016/j.ccell.2022.06.011↗
- Ronald Anthony Depinho · 3 shared papers, 1 shared grant, 2020–2025 · strength 0.99
- Yang Chen · 6 shared papers, 2018–2024 · strength 0.83
- Paper Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. DOI 10.1126/science.adh4567↗
- Paper Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis … DOI 10.1016/j.devcel.2023.07.025↗
- Paper Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic … DOI 10.1016/j.ccell.2021.02.007↗
- Haoqiang Ying · 3 shared papers, 2023–2025 · strength 0.58
- Paper Genetics and biology of pancreatic ductal adenocarcinoma. DOI 10.1101/gad.351863.124↗
- Paper Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis … DOI 10.1016/j.devcel.2023.07.025↗
- Paper KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated ki… DOI 10.1016/j.ccell.2023.07.002↗
- Huamin Wang · 1 shared paper, 1 shared grant, 2022–2025 · strength 0.57
- Huamin Wang · 4 shared papers, 2017–2024 · strength 0.54
- Paper Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. DOI 10.1126/science.adh4567↗
- Paper Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic … DOI 10.1016/j.ccell.2021.02.007↗
- Paper Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to pr… DOI 10.1016/j.ccell.2022.06.011↗
- Sónia A. Melo · 7 shared papers, 2014–2022 · strength 0.53
- Paper Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. DOI 10.1038/s41586-022-05062-9↗
- Paper Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumou… DOI 10.1136/gutjnl-2021-324994↗
- Paper Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. DOI 10.1038/nature22341↗
- Christoph Kahlert · 5 shared papers, 2014–2026 · strength 0.52
- Paper Oncogenic KRAS Regulates Secretion of Extracellular Vesicles and Surface Membrane Charge via Regulation of Phosphatidyl… DOI 10.1021/acsnano.6c08263↗
- Paper Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. DOI 10.1038/s41586-022-05062-9↗
- Paper Multiple antibodies identify glypican-1 associated with exosomes from pancreatic cancer cells and serum from patients w… DOI 10.1101/145706↗
- Phillip Andrew Futreal · 1 shared paper, 1 shared grant, 2014–2025 · strength 0.49
- Timothy Paul Heffernan · 3 shared papers, 2023–2026 · strength 0.48
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreat… DOI 10.1126/scitranslmed.adt5511↗
- Paper KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated ki… DOI 10.1016/j.ccell.2023.07.002↗
- Paola A. Guerrero · 3 shared papers, 2023–2026 · strength 0.48
- Paper CDK8 remodels the tumor microenvironment and promotes resistance to KRAS G12D inhibitors and daraxonrasib in PDAC. DOI 10.1038/s44318-026-00854-5↗
- Paper An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreat… DOI 10.1126/scitranslmed.adt5511↗
- Paper KRAS G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated ki… DOI 10.1016/j.ccell.2023.07.002↗
- David R Piwnica-Worms · 2 shared papers, 1 shared grant, 2015–2022 · strength 0.46
- Grant Employing mouse models to translate early detection of pancreas cancer R01CA195733↗
- Paper Author Correction: Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. DOI 10.1038/s41586-022-05062-9↗
- Paper Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. DOI 10.1038/nature14581↗
- Julienne L. Carstens · 5 shared papers, 2015–2022 · strength 0.46
- Paper Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis i… DOI 10.1016/j.celrep.2021.108990↗
- Paper Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resis… DOI 10.1158/2159-8290.cd-20-1484↗
- Paper Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent me… DOI 10.15252/emmm.201809085↗
- Cyril Henri Benes · 1 shared grant, 2025 · strength 0.45
- Gerald C Chu · 1 shared grant, 2025 · strength 0.45
- NABEEL El-BARDEESY · 1 shared grant, 2025 · strength 0.45
- Ralph Weissleder · 1 shared grant, 2025 · strength 0.45
- Lewis C. Cantley · 1 shared grant, 2025 · strength 0.45
- Sarah P. Thayer · 1 shared grant, 2025 · strength 0.45
- James wesley Horner · 1 shared grant, 2025 · strength 0.45
- Tyler Jacks · 1 shared grant, 2025 · strength 0.45
- Craig D. Logsdon · 1 shared grant, 2019 · strength 0.40
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.